Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Pier Luigi Zinzani, Jiri Mayer, Christopher Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qing-Yuan Zhang, Marco Brociner, Krimo Bouabdallah, Peter S. Ganly, Huilai Zhang, Sam Yuen, Marek Trneny, Rebecca Auer, Sha Huang, Jiayi Shen, Jamie Hirata, Judith Trotman

Blood (2025) 146 (Supplement 1): 227.

https://doi.org/10.1182/blood-2025-227

Published: 2025

Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2025-2129

Published: 2025

Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman

Blood (2025) 146 (Supplement 1): 8245.

https://doi.org/10.1182/blood-2025-8245

Published: 2025